Arcellx Key Executives
This section highlights Arcellx's key executives, including their titles and compensation details.
Find Contacts at Arcellx
(Showing 0 of )
Arcellx Earnings
This section highlights Arcellx's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
$63.71
Stock Price
$3.50B
Market Cap
163
Employees
Gaithersburg, MD
Location
Financial Statements
Access annual & quarterly financial statements for Arcellx, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $107.94M | $110.32M | $- | $- | $- |
| Cost of Revenue | $- | $- | $2.22M | $1.04M | $629.00K |
| Gross Profit | $107.94M | $110.32M | $-2.22M | $-1.04M | $-629.00K |
| Gross Profit Ratio | 100.00% | 100.00% | - | - | - |
| Research and Development Expenses | $157.09M | $133.85M | $149.56M | $46.88M | $25.06M |
| General and Administrative Expenses | $88.41M | $66.35M | $41.70M | $18.14M | $7.04M |
| Selling and Marketing Expenses | $- | $-1 | $- | $- | $- |
| Selling General and Administrative Expenses | $88.41M | $66.35M | $41.70M | $18.14M | $7.04M |
| Other Expenses | $- | $- | $- | $49.00K | $1.00K |
| Operating Expenses | $245.51M | $200.20M | $191.26M | $65.02M | $32.10M |
| Cost and Expenses | $245.51M | $200.20M | $191.26M | $65.02M | $32.10M |
| Interest Income | $33.32M | $23.70M | $4.30M | $300.00K | $1.00K |
| Interest Expense | $1.03M | $3.84M | $1.72M | $10.00K | $- |
| Depreciation and Amortization | $5.19M | $2.04M | $2.22M | $1.04M | $629.00K |
| EBITDA | $-99.06M | $-64.14M | $-184.74M | $-63.93M | $-31.47M |
| EBITDA Ratio | -91.78% | -58.15% | - | - | - |
| Operating Income | $-137.57M | $-89.88M | $-191.26M | $-65.02M | $-32.10M |
| Operating Income Ratio | -127.46% | -81.47% | - | - | - |
| Total Other Income Expenses Net | $32.29M | $19.85M | $2.58M | $49.00K | $1.00K |
| Income Before Tax | $-105.28M | $-70.03M | $-188.68M | $-64.97M | $-32.09M |
| Income Before Tax Ratio | -97.54% | -63.48% | - | - | - |
| Income Tax Expense | $2.07M | $663.00K | $-2.58M | $-1.04M | $422.70K |
| Net Income | $-107.35M | $-70.69M | $-186.10M | $-63.93M | $-32.09M |
| Net Income Ratio | -99.46% | -64.08% | - | - | - |
| EPS | $-2.00 | $-1.47 | $-4.22 | $-1.91 | $-1.47 |
| EPS Diluted | $-2.00 | $-1.47 | $-4.22 | $-1.91 | $-1.47 |
| Weighted Average Shares Outstanding | 53.57M | 48.06M | 44.11M | 33.54M | 21.78M |
| Weighted Average Shares Outstanding Diluted | 53.57M | 48.06M | 44.11M | 33.54M | 21.78M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.27M | $26.03M | $27.38M | $39.26M | $63.15M | $14.96M | $14.30M | $17.91M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $1.24M | $826.00K | $722.00K | $447.00K | $698.00K | $742.00K | $727.00K | $660.00K | $22.08M | $323.00K | $331.00K | $253.00K | $- | $207.00K | $165.00K |
| Gross Profit | $15.27M | $26.03M | $26.14M | $38.43M | $62.43M | $14.51M | $13.60M | $17.17M | $-727.00K | $-660.00K | $-22.08M | $-323.00K | $-331.00K | $-253.00K | $- | $-207.00K | $-165.00K |
| Gross Profit Ratio | 100.00% | 100.00% | 95.48% | 97.90% | 98.86% | 97.01% | 95.12% | 95.86% | - | - | - | - | - | - | - | - | - |
| Research and Development Expenses | $44.65M | $39.17M | $40.95M | $32.32M | $28.78M | $43.81M | $28.33M | $32.93M | $25.94M | $83.47M | $22.08M | $24.40M | $13.39M | $12.32M | $12.64M | $8.52M | $6.92M |
| General and Administrative Expenses | $23.77M | $20.47M | $21.42M | $22.75M | $19.36M | $16.01M | $15.54M | $15.44M | $14.06M | $10.40M | $9.21M | $8.03M | $7.30M | $4.79M | $3.29M | $2.76M | $2.17M |
| Selling and Marketing Expenses | $- | $- | $-1.24M | $-826.00K | $-722.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $23.77M | $20.47M | $20.18M | $21.92M | $18.64M | $16.01M | $15.54M | $15.44M | $14.06M | $10.40M | $9.21M | $8.03M | $7.30M | $4.79M | $3.29M | $2.76M | $2.17M |
| Other Expenses | $- | $- | $1.24M | $- | $- | $- | $- | $- | $- | $1.00M | $518.00K | $50.00K | $28.00K | $19.00K | $1.00K | $1.00K | $- |
| Operating Expenses | $68.42M | $59.65M | $61.14M | $54.24M | $47.43M | $59.82M | $43.86M | $48.37M | $40.00M | $93.88M | $31.29M | $32.44M | $20.70M | $17.11M | $15.93M | $11.28M | $9.09M |
| Cost and Expenses | $68.42M | $59.65M | $62.38M | $55.07M | $48.15M | $59.82M | $43.86M | $48.37M | $40.00M | $93.88M | $31.29M | $32.44M | $20.70M | $17.11M | $15.93M | $11.28M | $9.09M |
| Interest Income | $7.58M | $8.09M | $8.45M | $9.20M | $6.44M | $6.48M | $6.30M | $4.47M | $1.01M | $1.60M | $521.00K | $54.00K | $- | $- | $- | $- | $- |
| Interest Expense | $7.00K | $114.00K | $321.00K | $588.00K | $977.00K | $959.00K | $880.00K | $1.03M | $4.30M | $596.00K | $3.00K | $4.00K | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $1.79M | $1.33M | $1.24M | $826.00K | $722.00K | $447.00K | $698.00K | $742.00K | $727.00K | $660.00K | $514.00K | $323.00K | $331.00K | $253.00K | $250.00K | $207.00K | $165.00K |
| EBITDA | $-43.78M | $-24.20M | $-25.30M | $-5.78M | $22.16M | $-37.94M | $-22.56M | $-25.25M | $-38.27M | $-92.21M | $-30.26M | $-25.72M | $-20.37M | $-16.86M | $-15.68M | $-11.07M | $-8.93M |
| EBITDA Ratio | -286.78% | -92.95% | -92.39% | -14.73% | 35.10% | -253.63% | -157.73% | -140.95% | - | - | - | - | - | - | - | - | - |
| Operating Income | $-53.15M | $-33.62M | $-34.99M | $-15.81M | $15.00M | $-44.86M | $-29.56M | $-30.46M | $-40.00M | $-93.88M | $-31.29M | $-32.44M | $-20.70M | $-17.11M | $-15.93M | $-11.28M | $-9.09M |
| Operating Income Ratio | -348.17% | -129.14% | -127.79% | -40.27% | 23.75% | -299.94% | -206.68% | -170.04% | - | - | - | - | - | - | - | - | - |
| Total Other Income Expenses Net | $7.58M | $7.97M | $8.13M | $8.61M | $5.47M | $5.52M | $5.42M | $3.44M | $1.01M | $1.00M | $518.00K | $50.00K | $28.00K | $19.00K | $1.00K | $1.00K | $1.00K |
| Income Before Tax | $-45.58M | $-25.64M | $-26.86M | $-7.20M | $20.47M | $-39.34M | $-24.14M | $-27.02M | $-38.99M | $-92.87M | $-30.77M | $-32.38M | $-20.67M | $-17.09M | $-15.93M | $-11.28M | $-9.09M |
| Income Before Tax Ratio | -298.55% | -98.52% | -98.09% | -18.34% | 32.41% | -263.03% | -168.76% | -150.82% | - | - | - | - | - | - | - | - | - |
| Income Tax Expense | $1.50M | $223.00K | $341.00K | $782.72K | $622.00K | $6.00K | $-282.00K | $329.00K | $-1.58M | $-1.00M | $521.00K | $-50.00K | $-331.00K | $- | $- | $- | $- |
| Net Income | $-47.08M | $-25.87M | $-27.20M | $-7.20M | $19.84M | $-39.34M | $-23.85M | $-27.02M | $-38.99M | $-92.87M | $-30.77M | $-32.38M | $-20.67M | $-17.09M | $-15.93M | $-11.28M | $-9.09M |
| Net Income Ratio | -308.40% | -99.37% | -99.34% | -18.34% | 31.42% | -262.99% | -166.79% | -150.82% | - | - | - | - | - | - | - | - | - |
| EPS | $-0.88 | $-0.48 | $-0.51 | $-0.14 | $0.38 | $-0.81 | $-0.50 | $-0.58 | $-0.88 | $-2.12 | $-0.84 | $-1.56 | $-0.62 | $-0.78 | $-0.73 | $-0.52 | $-0.42 |
| EPS Diluted | $-0.88 | $-0.48 | $-0.51 | $-0.14 | $0.38 | $-0.81 | $-0.50 | $-0.58 | $-0.88 | $-2.12 | $-0.84 | $-1.56 | $-0.62 | $-0.78 | $-0.73 | $-0.52 | $-0.42 |
| Weighted Average Shares Outstanding | 53.69M | 53.82M | 53.52M | 52.76M | 52.28M | 48.44M | 48.11M | 46.77M | 44.11M | 43.82M | 36.61M | 20.76M | 33.54M | 21.78M | 21.78M | 21.78M | 21.78M |
| Weighted Average Shares Outstanding Diluted | 53.69M | 53.82M | 53.52M | 52.76M | 52.28M | 48.44M | 48.11M | 46.77M | 44.11M | 43.82M | 36.61M | 20.76M | 33.54M | 21.78M | 21.78M | 21.78M | 21.78M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $104.58M | $394.58M | $64.18M | $104.62M | $46.60M |
| Short Term Investments | $481.70M | $307.43M | $190.66M | $73.78M | $- |
| Cash and Short Term Investments | $587.38M | $702.02M | $254.84M | $104.62M | $46.60M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $11.94M | $14.35M | $12.03M | $8.19M | $2.76M |
| Total Current Assets | $599.31M | $716.36M | $266.86M | $112.81M | $49.36M |
| Property Plant Equipment Net | $70.25M | $69.83M | $39.89M | $10.32M | $4.90M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $38.28M | $27.17M | $2.50M | $199.00K | $199.00K |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $3.50M | $11.77M | $4.56M | $5.46M | $3.24M |
| Total Non-Current Assets | $112.02M | $108.77M | $46.95M | $15.97M | $8.34M |
| Other Assets | $- | $1 | $- | $- | $- |
| Total Assets | $711.33M | $825.13M | $313.82M | $128.78M | $57.69M |
| Account Payables | $2.10M | $2.62M | $9.05M | $1.33M | $504.00K |
| Short Term Debt | $7.54M | $47.75M | $35.96M | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $59.06M | $50.53M | $- | $183.00K | $- |
| Other Current Liabilities | $56.72M | $18.30M | $11.68M | $13.51M | $4.77M |
| Total Current Liabilities | $125.41M | $118.24M | $56.69M | $14.85M | $5.27M |
| Long Term Debt | $46.54M | $50.84M | $52.17M | $- | $- |
| Deferred Revenue Non-Current | $76.00M | $170.67M | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $8.59M | $- | $- | $235.45M | $116.14M |
| Total Non-Current Liabilities | $131.13M | $221.51M | $52.17M | $235.45M | $116.14M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $256.54M | $339.75M | $108.86M | $250.30M | $121.41M |
| Preferred Stock | $- | $- | $- | $28.89M | $114.26M |
| Common Stock | $53.00K | $52.00K | $44.00K | $1.00K | $1.00K |
| Retained Earnings | $-496.83M | $-389.48M | $-318.79M | $-130.11M | $-65.14M |
| Accumulated Other Comprehensive Income Loss | $848.00K | $547.00K | $-221.00K | $-20.00K | $-114.26M |
| Other Total Stockholders Equity | $950.72M | $874.26M | $523.92M | $397.31M | $115.68M |
| Total Stockholders Equity | $454.79M | $485.38M | $204.95M | $-121.52M | $-63.72M |
| Total Equity | $454.79M | $485.38M | $204.95M | $-121.52M | $-63.72M |
| Total Liabilities and Stockholders Equity | $711.33M | $825.13M | $313.82M | $128.78M | $57.69M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $711.33M | $825.13M | $313.82M | $128.78M | $57.69M |
| Total Investments | $519.97M | $334.60M | $190.66M | $73.78M | $199.00K |
| Total Debt | $54.08M | $97.62M | $88.13M | $100.00K | $- |
| Net Debt | $-51.60M | $-296.96M | $23.95M | $-104.52M | $-46.60M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | March 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $105.68M | $161.85M | $100.23M | $154.78M | $394.58M | $126.12M | $303.67M | $274.89M | $64.18M | $56.76M | $164.54M | $127.16M | $104.62M | $70.03M | $-46.60M | $46.60M |
| Short Term Investments | $481.70M | $412.41M | $416.66M | $419.35M | $307.43M | $313.60M | $202.82M | $258.70M | $190.66M | $224.02M | $142.45M | $83.77M | $73.78M | $61.16M | $93.19M | $- |
| Cash and Short Term Investments | $587.38M | $574.25M | $516.90M | $574.13M | $702.02M | $439.72M | $506.48M | $533.59M | $254.84M | $280.78M | $306.99M | $210.93M | $104.62M | $131.18M | $46.60M | $46.60M |
| Net Receivables | $- | $- | $- | $- | $- | $33.16M | $29.43M | $21.23M | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $1 | $- | $- | $-38.60M | $9.35M | $2 | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $11.94M | $13.05M | $13.52M | $11.51M | $14.35M | $13.14M | $22.16M | $16.54M | $12.03M | $16.43M | $18.76M | $9.97M | $8.19M | $2.96M | $- | $2.76M |
| Total Current Assets | $599.31M | $587.30M | $530.20M | $588.73M | $716.36M | $491.46M | $558.07M | $571.37M | $266.86M | $290.31M | $325.75M | $220.90M | $112.81M | $134.14M | $46.60M | $49.36M |
| Property Plant Equipment Net | $70.25M | $71.43M | $70.34M | $69.13M | $69.83M | $66.92M | $51.67M | $44.07M | $39.89M | $39.00M | $37.11M | $13.38M | $10.32M | $6.78M | $- | $4.90M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $38.28M | $102.43M | $132.55M | $119.52M | $27.17M | $42.96M | $2.50M | $2.50M | $2.50M | $2.50M | $2.50M | $199.00K | $199.00K | $- | $- | $199.00K |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $3.50M | $3.75M | $1.22M | $2.32M | $-97.00M | $-109.88M | $-2.50M | $-2.50M | $4.56M | $5.52M | $9.97M | $8.91M | $5.46M | $4.04M | $-46.60M | $3.24M |
| Total Non-Current Assets | $112.02M | $177.61M | $204.10M | $190.96M | $97.00M | $109.88M | $51.67M | $44.07M | $46.95M | $47.02M | $49.58M | $22.49M | $15.97M | $10.82M | $-46.60M | $8.34M |
| Other Assets | $- | $- | $- | $- | $11.77M | $12.88M | $13.79M | $7.51M | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $711.33M | $764.91M | $734.31M | $779.70M | $825.13M | $614.22M | $623.53M | $622.94M | $313.82M | $337.33M | $375.33M | $243.39M | $128.78M | $144.96M | $- | $57.69M |
| Account Payables | $2.10M | $5.99M | $4.87M | $3.10M | $2.62M | $7.18M | $5.69M | $4.53M | $9.05M | $2.96M | $7.56M | $1.87M | $1.33M | $1.58M | $- | $504.00K |
| Short Term Debt | $7.54M | $18.12M | $52.84M | $39.68M | $46.78M | $109.74M | $88.31M | $80.48M | $35.96M | $61.21M | $4.63M | $370.00K | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $59.06M | $- | $14.97M | $31.19M | $50.53M | $94.18M | $93.88M | $107.29M | $- | $- | $20.40M | $- | $183.00K | $- | $- | $- |
| Other Current Liabilities | $56.72M | $112.91M | $15.61M | $33.93M | $18.30M | $-37.95M | $-31.77M | $-26.24M | $11.68M | $-19.39M | $19.87M | $14.56M | $13.51M | $11.68M | $- | $4.77M |
| Total Current Liabilities | $125.41M | $137.02M | $88.29M | $107.90M | $118.24M | $173.15M | $156.11M | $166.06M | $56.69M | $44.78M | $32.05M | $16.81M | $14.85M | $13.26M | $- | $5.27M |
| Long Term Debt | $46.54M | $47.21M | $95.74M | $47.69M | $50.84M | $107.70M | $98.96M | $94.81M | $52.17M | $112.53M | $27.20M | $4.84M | $- | $206.00K | $- | $- |
| Deferred Revenue Non-Current | $76.00M | $- | $96.08M | $112.07M | $170.67M | $121.09M | $124.27M | $105.76M | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $-1 | $- | $-170.67M | $-121.09M | $-124.27M | $-105.76M | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $8.59M | $97.66M | $-32.97M | $15.47M | $- | $-53.85M | $-49.48M | $-47.41M | $- | $-56.27M | $117.00K | $147.00K | $235.45M | $235.29M | $- | $116.14M |
| Total Non-Current Liabilities | $131.13M | $144.87M | $158.85M | $175.22M | $221.51M | $174.94M | $173.75M | $153.17M | $52.17M | $56.27M | $27.32M | $4.99M | $235.45M | $235.50M | $- | $116.14M |
| Other Liabilities | $- | $- | $1 | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $256.54M | $281.89M | $247.14M | $283.12M | $339.75M | $348.09M | $329.86M | $319.23M | $108.86M | $101.04M | $59.37M | $21.80M | $250.30M | $248.76M | $- | $121.41M |
| Preferred Stock | $- | $- | $- | $- | $- | $65.00K | $7.00K | $- | $- | $337.33M | $1 | $246.98M | $233.38M | $233.38M | $114.26M | $114.26M |
| Common Stock | $53.00K | $53.00K | $53.00K | $53.00K | $52.00K | $48.00K | $48.00K | $48.00K | $44.00K | $44.00K | $44.00K | $36.00K | $1.00K | $1.00K | $- | $1.00K |
| Retained Earnings | $-496.83M | $-449.75M | $-423.88M | $-396.68M | $-389.48M | $-409.32M | $-369.99M | $-346.13M | $-318.79M | $-279.80M | $-194.59M | $-162.50M | $-130.11M | $-109.44M | $- | $-65.14M |
| Accumulated Other Comprehensive Income Loss | $848.00K | $1.90M | $-792.00K | $-512.00K | $547.00K | $-65.00K | $-7.00K | $86.00K | $-221.00K | $-399.00K | $-262.00K | $-44.00K | $-20.00K | $-5.00K | $-63.72M | $-114.26M |
| Other Total Stockholders Equity | $950.72M | $930.81M | $911.78M | $893.71M | $874.26M | $675.47M | $663.61M | $649.72M | $523.92M | $516.44M | $510.76M | $384.10M | $-216.15M | $-227.73M | $- | $115.68M |
| Total Stockholders Equity | $454.79M | $483.02M | $487.16M | $496.57M | $485.38M | $266.13M | $293.67M | $303.72M | $204.95M | $236.28M | $315.96M | $221.59M | $-121.52M | $-103.80M | $50.54M | $-63.72M |
| Total Equity | $454.79M | $483.02M | $487.16M | $496.57M | $485.38M | $266.13M | $293.67M | $303.72M | $204.95M | $236.28M | $315.96M | $221.59M | $-121.52M | $-103.80M | $50.54M | $-63.72M |
| Total Liabilities and Stockholders Equity | $711.33M | $764.91M | $734.31M | $779.70M | $825.13M | $614.22M | $623.53M | $622.94M | $313.82M | $337.33M | $375.33M | $243.39M | $128.78M | $144.96M | $50.54M | $57.69M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $711.33M | $764.91M | $734.31M | $779.70M | $825.13M | $614.22M | $623.53M | $622.94M | $313.82M | $337.33M | $375.33M | $243.39M | $128.78M | $144.96M | $50.54M | $57.69M |
| Total Investments | $519.97M | $514.84M | $549.21M | $538.87M | $334.60M | $356.56M | $202.82M | $258.70M | $190.66M | $224.02M | $142.45M | $83.77M | $73.78M | $61.16M | $93.19M | $199.00K |
| Total Debt | $54.08M | $65.33M | $74.29M | $87.36M | $97.62M | $108.72M | $93.64M | $87.65M | $88.13M | $86.87M | $29.51M | $5.21M | $100.00K | $206.00K | $- | $- |
| Net Debt | $-51.60M | $-96.51M | $-25.94M | $-67.42M | $-296.96M | $-17.40M | $-210.03M | $-187.24M | $23.95M | $30.11M | $-135.03M | $-121.95M | $-104.52M | $-69.82M | $46.60M | $-46.60M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-107.35M | $-70.69M | $-188.68M | $-64.97M | $-32.09M |
| Depreciation and Amortization | $-10.27M | $2.04M | $1.32M | $1.04M | $629.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-3.64M |
| Stock Based Compensation | $61.09M | $41.79M | $21.54M | $6.75M | $1.05M |
| Change in Working Capital | $-30.78M | $225.43M | $4.45M | $2.72M | $1.75M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $-70.00K | $-6.47M | $7.42M | $974.00K | $-1.33M |
| Other Working Capital | $-30.71M | $231.90M | $-2.97M | $1.75M | $3.09M |
| Other Non Cash Items | $3.84M | $9.01M | $62.06M | $213.00K | $3.64M |
| Net Cash Provided by Operating Activities | $-83.47M | $207.57M | $-99.30M | $-54.24M | $-28.66M |
| Investments in Property Plant and Equipment | $-13.43M | $-21.43M | $-2.28M | $-5.78M | $-888.00K |
| Acquisitions Net | $- | $- | $115.40M | $- | $- |
| Purchases of Investments | $-597.31M | $-442.43M | $-273.74M | $-74.19M | $- |
| Sales Maturities of Investments | $427.70M | $309.35M | $158.34M | $- | $- |
| Other Investing Activities | $- | $- | $-115.40M | $-74.19M | $- |
| Net Cash Used for Investing Activities | $-183.04M | $-154.51M | $-117.67M | $-79.98M | $-888.00K |
| Debt Repayment | $-39.85M | $-29.39M | $-9.68M | $-387.00K | $- |
| Common Stock Issued | $- | $299.71M | $259.83M | $- | $41.66M |
| Common Stock Repurchased | $1.16M | $- | $- | $-24.00K | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $15.76M | $8.85M | $2.47M | $118.86M | $41.66M |
| Net Cash Used Provided by Financing Activities | $-24.09M | $279.16M | $252.62M | $118.45M | $41.66M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-290.60M | $332.22M | $35.65M | $-15.76M | $12.11M |
| Cash at End of Period | $108.31M | $398.90M | $66.68M | $31.03M | $46.80M |
| Cash at Beginning of Period | $398.90M | $66.68M | $31.03M | $46.80M | $34.69M |
| Operating Cash Flow | $-83.47M | $207.57M | $-99.30M | $-54.24M | $-28.66M |
| Capital Expenditure | $-13.43M | $-21.43M | $-2.28M | $-5.78M | $-888.00K |
| Free Cash Flow | $-96.90M | $186.15M | $-101.58M | $-60.02M | $-29.55M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-47.08M | $-25.87M | $-27.20M | $-7.20M | $19.84M | $-39.34M | $-23.85M | $-27.34M | $-38.99M | $-85.21M | $-30.77M | $-32.38M | $-20.67M | $-17.09M | $-15.93M | $-11.28M | $-9.09M |
| Depreciation and Amortization | $1.79M | $1.33M | $1.24M | $826.00K | $722.00K | $447.00K | $439.00K | $432.00K | $417.00K | $339.00K | $302.00K | $416.00K | $331.00K | $253.00K | $250.00K | $207.00K | $165.00K |
| Deferred Income Tax | $- | $- | $-341.00K | $- | $5.13M | $-2.42M | $-2.71M | $- | $- | $- | $- | $- | $-44.30M | $- | $- | $- | $- |
| Stock Based Compensation | $15.77M | $15.33M | $15.14M | $14.85M | $10.62M | $10.61M | $10.40M | $10.16M | $5.79M | $5.33M | $5.94M | $4.48M | $2.90M | $1.86M | $1.24M | $757.00K | $343.00K |
| Change in Working Capital | $-12.73M | $43.19M | $-21.48M | $-39.76M | $30.02M | $3.36M | $-6.71M | $198.76M | $6.78M | $-365.00K | $1.84M | $-5.27M | $-4.26M | $2.69M | $3.48M | $810.00K | $1.30M |
| Accounts Receivables | $- | $- | $- | $- | $31.48M | $-2.05M | $-8.20M | $-21.23M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $-1.56M | $5.60M | $-4.04M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $-3.58M | $908.00K | $2.30M | $307.00K | $-4.83M | $2.15M | $440.00K | $-4.24M | $5.92M | $-4.17M | $4.97M | $696.00K | $-105.00K | $79.00K | $679.00K | $321.00K | $-223.00K |
| Other Working Capital | $-9.15M | $42.28M | $-23.78M | $-40.07M | $4.92M | $-2.35M | $5.09M | $224.23M | $850.00K | $3.81M | $-3.13M | $-5.96M | $-4.15M | $2.61M | $2.80M | $489.00K | $1.53M |
| Other Non Cash Items | $-3.78M | $-3.27M | $11.37M | $15.57M | $-8.07M | $17.23M | $-184.00K | $37.00K | $-1.51M | $63.26M | $212.00K | $170.00K | $44.45M | $63.00K | $679.00K | $850.00K | $-223.00K |
| Net Cash Provided by Operating Activities | $-46.03M | $30.72M | $-36.25M | $-31.91M | $58.25M | $-10.10M | $-22.61M | $182.04M | $-27.52M | $-16.65M | $-22.55M | $-32.59M | $-21.55M | $-12.22M | $-10.96M | $-9.51M | $-7.28M |
| Investments in Property Plant and Equipment | $-1.50M | $-2.29M | $-3.21M | $-6.43M | $-5.29M | $-7.93M | $-7.23M | $-980.00K | $-1.28M | $-385.00K | $-149.00K | $-467.00K | $-4.75M | $216.00K | $-180.00K | $-1.07M | $-608.00K |
| Acquisitions Net | $- | $- | $- | $- | $-65.79M | $152.10M | $- | $65.79M | $-34.90M | $81.03M | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-136.32M | $-59.95M | $-82.66M | $-318.38M | $-42.38M | $-237.90M | $- | $-162.14M | $-25.76M | $-128.61M | $-92.35M | $-27.03M | $-12.91M | $-61.28M | $- | $- | $- |
| Sales Maturities of Investments | $133.70M | $98.00M | $78.00M | $118.00M | $68.69M | $85.80M | $58.50M | $96.35M | $60.66M | $47.57M | $33.26M | $16.85M | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $-4.66M | $-200.38M | $65.79M | $-152.10M | $58.50M | $-65.79M | $34.90M | $-81.03M | $-59.08M | $-10.18M | $-12.91M | $-61.28M | $- | $- | $- |
| Net Cash Used for Investing Activities | $-4.12M | $35.76M | $-7.87M | $-206.81M | $21.02M | $-160.03M | $51.27M | $-66.77M | $33.62M | $-81.42M | $-59.23M | $-10.64M | $-17.66M | $-61.07M | $-180.00K | $-1.07M | $-608.00K |
| Debt Repayment | $-10.54M | $-8.36M | $-13.36M | $-7.59M | $-15.38M | $-5.70M | $-3.38M | $-4.93M | $-380.00K | $-9.24M | $-30.00K | $-29.00K | $-28.00K | $-29.00K | $-209.00K | $-121.00K | $- |
| Common Stock Issued | $- | $-7.54M | $2.94M | $4.60M | $199.71M | $- | $3.49M | $100.00M | $129.97M | $-472.00K | $121.49M | $139.16M | $119.12M | $- | $- | $81.75M | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-472.00K | $- | $- | $- | $- | $-24.00K | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $4.52M | $3.70M | $2.94M | $4.60M | $4.27M | $- | $3.49M | $374.00K | $1.69M | $344.00K | $- | $429.00K | $43.00K | $-438.00K | $37.51M | $81.75M | $42.89M |
| Net Cash Used Provided by Financing Activities | $-6.02M | $-4.66M | $-10.43M | $-2.98M | $188.59M | $-4.99M | $116.00K | $95.44M | $1.31M | $-9.71M | $121.46M | $139.56M | $15.00K | $-467.00K | $37.27M | $81.63M | $42.89M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-167.36M | $185.73M | $-18.37M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-56.17M | $61.82M | $-54.55M | $-241.70M | $270.37M | $-175.12M | $28.77M | $210.71M | $7.42M | $-107.78M | $39.68M | $96.33M | $-39.19M | $-73.76M | $26.13M | $71.06M | $35.00M |
| Cash at End of Period | $108.31M | $164.47M | $100.23M | $154.78M | $396.49M | $131.05M | $306.17M | $277.39M | $66.68M | $59.26M | $167.04M | $127.36M | $31.03M | $70.23M | $143.98M | $117.85M | $46.80M |
| Cash at Beginning of Period | $164.47M | $102.65M | $154.78M | $396.49M | $126.12M | $306.17M | $277.39M | $66.68M | $59.26M | $167.04M | $127.36M | $31.03M | $70.23M | $143.98M | $117.85M | $46.80M | $11.79M |
| Operating Cash Flow | $-46.03M | $30.72M | $-36.25M | $-31.91M | $58.25M | $-10.10M | $-22.61M | $182.04M | $-27.52M | $-16.65M | $-22.55M | $-32.59M | $-21.55M | $-12.22M | $-10.96M | $-9.51M | $-7.28M |
| Capital Expenditure | $-1.50M | $-2.29M | $-3.21M | $-6.43M | $-5.29M | $-7.93M | $-7.23M | $-980.00K | $-1.28M | $-385.00K | $-149.00K | $-467.00K | $-4.75M | $216.00K | $-180.00K | $-1.07M | $-608.00K |
| Free Cash Flow | $-47.53M | $28.43M | $-39.46M | $-38.34M | $52.95M | $-18.03M | $-29.84M | $181.06M | $-28.80M | $-17.03M | $-22.70M | $-33.05M | $-26.30M | $-12.01M | $-11.14M | $-10.57M | $-7.89M |
Arcellx Dividends
Explore Arcellx's dividend history, including dividend yield, payout ratio, and historical payments.
Arcellx News
Read the latest news about Arcellx, including recent articles, headlines, and updates.
Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointments of Andrew Galligan and Kristin Myers to its Board of Directors. Mr. Galligan is a proven financial executive who brings over three decades of strategic leadership experience to the Arcellx Board. Ms. Myers, a highly experienced healthcare.
Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Arcellx, Inc. (NASDAQ: ACLX) Chief Medical Officer Christopher Heery, M.D., and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University.
Arcellx Impressive Safety Data Leaves Doubts
Arcellx's innovative cell therapy platform shows promising potential in treating multiple myeloma, a significant unmet medical need. Strong clinical trial results and strategic partnerships bolster confidence in Arcellx's growth trajectory and market position. Clarity is needed around mechanistic differentiation on D-Domain safety results before fully buying into the story.
Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, at 1:10 p.m. ET. A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Investors s.
5 Biotech Breakthrough Stocks to Watch in 2025
After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services.
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
On Sunday, Arcellx, Inc. ACLX revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma (RRMM).
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data will be presented during an oral presentation at the 66th American Society of.
Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma
Arcellx leverages proprietary platforms like D-Domain, ddCAR, and ARC-SparX to enhance immune response, targeting multiple myeloma, AML, MDS, and solid tumors. ACLX's lead therapy, anito-cel, shows strong clinical results in relapsed/refractory multiple myeloma, even for high-risk patients. Arcellx's strategic partnership with Kite Pharma validates its technology, potentially leading to milestone payments of up to $935 million.
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
The biotech industry has fallen on hard times over the last few years, no thanks to venture capital drying up, tighter regulatory conditions and the harsh reality of the post-pandemic healthcare environment. As a result, biotech breakthrough stocks fell out of favor with investors and were among the worst performers in the stock market.
Arcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market
Arcellx is advancing Anito-cel in a pivotal Phase 2 trial for relapsed or refractory multiple myeloma, showing promising early results. Anito-cel has demonstrated a 100% overall response rate and a 76% complete response rate in early trials. The collaboration with Kite enhances Arcellx's operational capabilities and financial stability, supporting the development of Anito-cel.
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
REDWOOD CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx's novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3,.
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
REDWOOD CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx's novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3,.
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
Biotech breakthrough stocks, along with the sector overall, faced significant challenges over the past two years, with venture capital drying up, shifts in the post-pandemic healthcare landscape and tighter regulatory conditions squeezing already-thin margins. However, 2024 may herald a resurgence for biotech stocks, spurred by an FDA approval spree throughout 2023.
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, at 12:45 p.m. ET. A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Inv.
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26, at 1:00 p.m. ET. A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in t.
Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference
REDWOOD CITY, Calif. , Feb. 29, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, at 2:50 p.m.
Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights
-- Expanded strategic partnership with Kite -- -- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory multiple myeloma -- -- Ended the quarter with $729.2M, extending cash runway into 2027 -- REDWOOD CITY, Calif. , Feb. 28, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2023.
The 3 Biotech Stocks That Could Make Your February Unforgettable
Following a hot year of M&A with biotech stocks, we'll see more of the same in 2024 as drug makers look to build their pipelines ahead of a massive patent cliff. Between now and 2028, pharmaceutical giants stand to lose billions in revenue as blockbuster drug patents expire.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ACLX.